<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064592</url>
  </required_header>
  <id_info>
    <org_study_id>APHP211236</org_study_id>
    <nct_id>NCT05064592</nct_id>
  </id_info>
  <brief_title>Retrospective Study on Prolonged Sedation Effects With Inhaled Agents in PICU</brief_title>
  <acronym>RESPIRE</acronym>
  <official_title>Retrospective Study on Prolonged Sedation Effects With Inhaled Agents in Pediatric Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effects of halogenated gases on sedation and&#xD;
      analgesia, to describe the tolerance and to determine the risk factors for failure, in&#xD;
      pediatric intensive care patients during prolonged sedation.&#xD;
&#xD;
      This study will be based on the medical records of patients hospitalized between 2015 and&#xD;
      2020.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sedation is a major therapeutic element in patients in intensive care under artificial&#xD;
      ventilation, in order to allow their comfort and patient-ventilator synchronization. The use&#xD;
      of benzodiazepines in combination with opioids is common practice. However, during prolonged&#xD;
      sedation, the effects wane, then the doses must be increased, responsible for an increase in&#xD;
      the incidence of a significant withdrawal syndrome in the recovery phase, a source of delay&#xD;
      in extubation or early reintubation.&#xD;
&#xD;
      The use of halogenated anesthetic gases is now possible in pediatric intensive care in these&#xD;
      patients on artificial ventilation.&#xD;
&#xD;
      Their efficacy and tolerance in prolonged use must be evaluated. Their use could improve the&#xD;
      sedative effects, reduce the doses of benzodiazepines and opioids used, and reduce unwanted&#xD;
      effects in terms of withdrawal syndrome.&#xD;
&#xD;
      The objective of the study is to evaluate the effects of halogenated gases on sedation and&#xD;
      analgesia, to describe the tolerance and to determine the risk factors for failure, in&#xD;
      pediatric intensive care patients during prolonged sedation.&#xD;
&#xD;
      This study will be based on the medical records of patients hospitalized between 2015 and&#xD;
      2020.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dosages of hypnotics first 24 hours following the introduction of halogens</measure>
    <time_frame>Day 0</time_frame>
    <description>Show a reduction in hypnotics dosages, calculated in Midazolam equivalent in µg / kg / h, during the first 24 hours after the introduction of halogens.&#xD;
A decrease will be significant if it is greater than 20% compared to the basal level before initiation of the halogens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosages of opioids in the 24 hours following the introduction of halogens</measure>
    <time_frame>Day 0</time_frame>
    <description>Show a reduction &gt; 20% in opioids dosages (calculated in morphine equivalent, in µg / kg / h, in the 24 hours following the introduction of halogens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosages of ketamine within 24 hours of the introduction of halogens</measure>
    <time_frame>Day 0</time_frame>
    <description>Show a reduction &gt;20% in ketamine dosages within 24 hours of the introduction of halogens (mg / kg / h).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphinic / hypnotic dosages at the end of halogenated use</measure>
    <time_frame>Day 0</time_frame>
    <description>Show a reduction &gt; 20% in morphinic / hypnotic dosages at the end of halogenated use (&gt; 24 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical sedation score</measure>
    <time_frame>Day 0</time_frame>
    <description>COMFORT BEHAVIOUR scale. Measures pain and excess sedation in intensive care, starting in the neonatal period.&#xD;
Score: from 6 to 30 :&#xD;
Excess sedation: 6 to 10 Comfortable child, sedated without excess: 11 to 17 Child in borderline condition, possible pain: 17 to 22 Child clearly uncomfortable, painful: 23 to 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypnotics / sedatives / curares dosages in populations of ARDS patients at the end of the use of halogens</measure>
    <time_frame>Day 0</time_frame>
    <description>Show a reduction&gt; 20% in hypnotics / sedatives / curares dosages (µg/kg/h) in populations of Acute Respiratory Distress Syndrome patients (ARDS patients) with and without extracorporeal membrane oxygenation (ECMO) at the end of the use of halogens (&gt; 24 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilatory parameters in patients with ARDS during the period of halogen use</measure>
    <time_frame>Day 0</time_frame>
    <description>Show a reduction &gt; 20% in ventilatory parameters (PEEP in mmHg, Tidal volume in ml, PaO2/FiO2 ratio) in patients with ARDS during the period of halogen use (&lt;24 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of sedation, analgesia and curarization</measure>
    <time_frame>Day 0</time_frame>
    <description>Determine the total duration of sedation, analgesia and curarization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Halogenated failure criteria</measure>
    <time_frame>Day 0</time_frame>
    <description>Comparison of patients who shown an improvement of the COMFORT B scale 24 hours after introducing halogenated between patients who shown no significant reduction of COMFORT B scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal syndrome: morphine and hypnotics</measure>
    <time_frame>Day 0</time_frame>
    <description>Determine the proportion of withdrawal syndrome : morphine and hypnotics in %.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tachyphylaxis to halogenated</measure>
    <time_frame>Day 0</time_frame>
    <description>Withdrawal syndrome within 24 hours of stopping halogenated: proportion of tachyphylaxis to halogenated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of secondary to prolonged administration of Sevoflurane or Isoflurane</measure>
    <time_frame>Day 0</time_frame>
    <description>Describe the proportions of side effects: Malignant hyperthermia, Arterial hypotension, Tachycardia, Bradypnea or apnea, Bronchospasm, Arrhythmias, Cytolytic hepatitis, Chills, nausea, vomiting upon awakening, Irritation of the respiratory tract, Headache.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Mechanical Ventilation</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Medical records of minor patients hospitalized between 2015 and 2020 in PICU and having been under sedation and prolonged invasive mechanical ventilation (&gt; 72h).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Minor patients hospitalized between 2015 and 2020 in PICU and having been under sedation&#xD;
        and prolonged invasive mechanical ventilation (&gt; 72h).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minor patient over 1 month old (and over 36 WA of corrected age) and under 18 years&#xD;
             old&#xD;
&#xD;
          -  Hospitalized in neonatal or pediatric intensive care unit&#xD;
&#xD;
          -  Invasive mechanical ventilation over 72 hours&#xD;
&#xD;
          -  Prolonged sedation greater than 72 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Opposition of the holders of parental authority of the minor patient or the adult patient&#xD;
        to the use of the data for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Louis Léger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Léo Berger, MD</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre-Louis Léger, MD, PhD</last_name>
    <phone>1 87 89 26 83</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre-louis.leger@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène Morel</last_name>
    <phone>1 71 19 63 46</phone>
    <phone_ext>+33</phone_ext>
    <email>helene.morel@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jordi Miatello, MD</last_name>
      <phone>1 45 21 32 05</phone>
      <phone_ext>+33</phone_ext>
      <email>jordi.miatello@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Léo Berger, MD</last_name>
      <phone>1 87 89 26 83</phone>
      <phone_ext>+33</phone_ext>
      <email>leo.berger@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Artificial ventilation</keyword>
  <keyword>Pediatric intensive care unit</keyword>
  <keyword>Prolonged sedation effects</keyword>
  <keyword>Halogenated anesthetic gases</keyword>
  <keyword>Inhaled agents</keyword>
  <keyword>Benzodiazepines in combination with opioids</keyword>
  <keyword>Halogenated anesthetic gases efficacity and tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

